PolyPid Ltd. has unveiled a significant expansion of its product pipeline with the introduction of PD01B, a new Kynatrix-based product candidate aimed at treating diabetic foot infections (DFIs). This announcement, made during a virtual Investor Day on October 28, 2026, marks a pivotal moment for the company as it seeks to transition its Kynatrix technology from infection prevention to treatment.

The introduction of PD01B is particularly important given the high incidence of DFIs among diabetes patients. According to PolyPid, diabetic foot infections are among the most serious complications of diabetes, affecting an estimated 589 million adults worldwide. The company’s CEO, Dikla Czaczkes Akselbrad, emphasized the urgency of addressing this issue, stating, “PD01B is our first step in extending Kynatrix from preventing infections to treating them.”

Background

PolyPid Ltd. is a biopharmaceutical company specializing in innovative treatments within the surgical and medical instruments sector (SIC: 3841). The company is publicly traded on Nasdaq under the ticker symbol PYPD. Founded with a mission to enhance treatment effectiveness, PolyPid focuses on developing long-acting, controlled-release drugs that deliver therapy directly at the site of care. Recent filings include several 6-K reports, with the latest being on October 28, 2026, where the company detailed its new product candidate.

What the Filing Says

The recent filing includes a press release announcing the expanded pipeline strategy and the introduction of PD01B. The release highlights that PD01B is designed for hyper-localized, controlled-release antibiotic treatment of DFIs. The product is based on PolyPid’s proprietary Kynatrix technology and is planned to be developed as a new New Drug Application (NDA). A pre-investigational new drug meeting and the first-in-human study are expected in the second half of 2027.

Impact

This development may significantly affect patients suffering from diabetic foot infections, as current treatments often rely on systemic antibiotics that are less effective due to poor blood supply in infected tissues. PD01B aims to provide high local concentrations of doxycycline, a broad-spectrum antibiotic, directly at the infection site, potentially improving treatment outcomes.

What's Next

PolyPid plans to continue its momentum with upcoming milestones, including the anticipated PDUFA goal date for its lead product, D-PLEX® 300, on November 28, 2026. The company is also expected to host further discussions on PD01B and its strategic vision during the Investor Day event, which includes a Q&A session with key opinion leaders.